Are Robust Financials Driving The Recent Rally In Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Stock?

Shanghai Allist Pharmaceuticals (SHSE:688578) has had a great run on the share market with its stock up by a significant 29% over the last three months. Given that the market rewards strong

Simply Wall StJul 19 18:13 ET

Shareholders Shanghai Aixiang and Shanghai Aiyun of Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) are planning to reduce their shareholding by no more than 4.5 million shares through block trade.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company's employee shareholding platform Shanghai Aixiang and Shanghai Aiyun plan to conduct bulk transactions...

Zhitong FinanceJul 19 10:05 ET

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): The controlling shareholder proposes to implement mid-year dividends in 2024.

On July 17th, Gelonhui announced that they received a letter from Mr. Du Jinhao and Ms. Qi Ju, the actual controller of Shanghai Allist Pharmaceuticals Co., Ltd., proposing to implement mid-term dividends for the company in 2024. In order to implement the core idea of "investors first", adhere to the business philosophy of bringing long-term and sustainable returns to investors, and enhance the sense of achievement for investors, based on their confidence in the company's long-term development, Mr. Du Jinhao and Ms. Qi Ju unanimously proposed to develop and implement profit distribution policies that comply with the "Company Law" principles and ensure normal operation and long-term development of the company.

Gelonghui FinanceJul 17 04:15 ET

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): Received drug clinical trial approval letter for new indication of Venetoclax.

On July 8th, Gelunhui reports that Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration. The clinical study of the new indication for sulfonic acid fumeitinib tablets (referred to as "fumeitinib") obtained drug clinical trial approval. Fumeitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which is a type 1 small molecule targeted drug independently developed by the company. Fumeitinib belongs to a highly selective and irreversible third-generation EGFR-TKI, mainly used in the treatment of EGFR mutation non-small cell lung cancer, with the potential to cross the blood-brain barrier.

Gelonghui FinanceJul 8 05:44 ET

HKEX Live | WuXi Biologics and Shanghai Allist Pharmaceuticals Co., Ltd. collaborate to conduct clinical research on combination therapy for advanced non-small cell lung cancer, and How Yu-B (02256) surges more than 8% in the afternoon.

Wah Yuet Group B (02256) rose more than 8% in the afternoon. As of press time, it has risen 7.14% to HKD 3.45 with a turnover of HKD 3.1682 million.

Zhitong FinanceJun 25 01:42 ET

With EPS Growth And More, Shanghai Allist Pharmaceuticals (SHSE:688578) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage

Simply Wall StJun 17 18:16 ET